Cutaneous adverse events associated with new cancer therapies
{{output}}
Purpose of review: Modern oncologic therapies, including immune checkpoint inhibitors (ICIs), targeted kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), bispecific antibodies, and adoptive cellular therapies, have transf... ...
